Bigfoot Biomedical was founded by people affected by and living with Type 1 Diabetes (T1D) and is committed to leveraging data, people, and smart technology to create a connected ecosystem of solutions that will deliver improved outcomes valued by patients, providers, and payers.
Bigfoot's investigational automated insulin delivery system, otherwise known as an "artificial pancreas," was inspired by a proof-of-concept system that's been used for over 50,000 hours.